About
Neuro Discovery Platform
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
720
By Phase
PHASE2: 2
By Status
ENROLLING_BY_INVITATION: 1RECRUITING: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07161700Lead Sponsor
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
PHASE2Enrolling by invitation
360 participants
Started: Sep 2, 2025 · Completed: May 31, 2027
NCT07065240Lead Sponsor
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
PHASE2Recruiting
360 participants
Started: Jun 19, 2025 · Completed: Mar 31, 2027
Funding History (1)
D
Oct 31, 2024
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...